Roivant Sciences Ltd (NASDAQ:ROIV) shares traded 4.44% higher at $10.81 on Wall Street last session.
In accordance with the data, 11 analysts cover Roivant Sciences Ltd (NASDAQ:ROIV). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $23.00 and a low of $11.00, we find $15.00. Given the previous closing price of $10.35, this indicates a potential upside of 44.93 percent. ROIV stock price is now 14.61% away from the 50-day moving average and 11.63% away from the 200-day moving average. The market capitalization of the company currently stands at $8.69B.
It has been rated a hold by 1 analysts and a buy by 10. Brokers who have rated the stock have averaged $15.56 as their price target over the next twelve months.
With the price target of $14, Deutsche Bank recently initiated with Buy rating for Roivant Sciences Ltd (NASDAQ: ROIV).
In other news, Venker Eric, Chief Operating Officer sold 153,027 shares of the company’s stock on Oct 05. The stock was sold for $1,547,103 at an average price of $10.11. Upon completion of the transaction, the Chief Operating Officer now directly owns 595,397 shares in the company, valued at $6.44 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 03, Chief Operating Officer Venker Eric sold 606,221 shares of the business’s stock. A total of $6,213,765 was realized by selling the stock at an average price of $10.25. This leaves the insider owning 595,397 shares of the company worth $6.44 million. A total of 32.37% of the company’s stock is owned by insiders.
Roivant Sciences Ltd (NASDAQ: ROIV) opened at $10.38 on Wednesday. During the past 12 months, Roivant Sciences Ltd has had a low of $6.43 and a high of $13.24. As of last week, the company has a debt-to-equity ratio of 0.53, a current ratio of 5.84, and a quick ratio of 5.82. The fifty day moving average price for ROIV is $9.43 and a two-hundred day moving average price translates $9.68 for the stock.
The latest earnings results from Roivant Sciences Ltd (NASDAQ: ROIV) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.4, missing analysts’ expectations of -$0.31 by -0.09. This compares to -$0.45 EPS in the same period last year. The net profit margin was -951.76% and return on equity was -103.96% for ROIV. The company reported revenue of $37.1 million for the quarter, compared to $12.53 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 196.03 percent. For the current quarter, analysts expect ROIV to generate $31.15M in revenue.
